POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
Jan 1, 2022, 00:00
10.1016/j.jval.2021.11.1300
https://www.valueinhealthjournal.com/article/S1098-3015(21)03095-3/fulltext
Title :
POSC399 Treatment Effect and Costs of the Complete Therapeutic Pathway in Patients with First-Line Castration-Resistant Prostate Cancer with Either First-Line Docetaxel or Abiraterone Acetate Plus Prednisone
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)03095-3&doi=10.1016/j.jval.2021.11.1300
First page :
Section Title :
Open access? :
No
Section Order :
10839